AlzWIN

"AlzWIN," SevenPointOne’s flagship solution, is a digital healthcare solution that uses AI to analyze just one minute of spoken voice data to quickly and accurately screen for the risk of cognitive decline. It detects changes in cognitive function early on through a simple, conversational test, without the need for complex medical interviews or costly tests.

AlzWIN has been validated at the global level through registration with the U.S. FDA. Recently, it successfully completed a confirmatory clinical trial for medical device approval from the Ministry of Food and Drug Safety (MFDS), securing strong clinical efficacy and technical reliability.

Ultra-Simple Screening: Identifies high-risk groups for cognitive decline using just one minute of voice data

Validated Domestically and Internationally: U.S. FDA registration and completion of MFDS confirmatory clinical trial

On-site, Customizable Scalability: Can be immediately implemented in senior care facilities, public health centers, hospitals and clinics, and even integrated into insurance provider care models.

AlzWIN provides the fastest and most accurate cognitive care standard, bridging the gap between daily life and clinical practice.